International Review of Ophthalmology

Previous Articles     Next Articles

Progress in the treatment of wet age-related macular degeneration with Ranibizumab

KONG Li1,  WANG Wen-juan2, HE Rong-hua3, ZHOU Guo-hong2   

  1. 1Department of Anatomy, Shanxi Medical University, Taiyuan 030001, China; 2Shanxi Eye Hospital, Taiyuan 030002, China; 3The First Clinical College of Shanxi Medical University, Taiyuan 030001, China.
  • Received:2016-08-21 Online:2016-12-22 Published:2016-12-21
  • Contact: ZHOU Guo-hong, Email: Guohongzhou2005@163.com
  • Supported by:
    The Key Science and Technology Program of the Health Department of Shanxi Province(2011057); Natural Science Foundation of Shanxi(2014011043-7)

Abstract:

Wet age\|related macular degeneration (AMD) is one of the main causes of vision loss in elderly people, and its etiology is not clear. In terms of pathogenesis, it has been confirmed that vascular endothelial growth factor and wet AMD have a clear correlation. Therefore, there are many kinds of anti\|vascular endothelial growth factor drugs used in the disease. Intravitreal Ranibizumab can inhibit vascular endothelial growth factor and block the growth and leakage of new blood vessels to play a role.The Ranibizumab has been shown to be a definite therapeutic effect in the treatment of wet AMD. The progress of Ranibizumab in the treatment of wet AMD is reviewed in this article, including the treatment efficacy, the factors of affecting the efficacy, the combined therapy, and the adverse reaction and so on.(Int Rev Ophthalmol, 2016, 40: 400-404)